Skip to Content

How You Can Help

Awardees

Funds raised by Sprint for Life are put to work finding new and innovative ways of diagnosing, treating and managing ovarian cancer.  $50,000 awards are given to MD Anderson faculty members to pursue specific research programs, with the combined goal of eliminating ovarian cancer. 

2014

Kelsey Mathieu, Ph.D.
Early detection ovarian cancer through nanomagnetic relaxometry

 

Yunfei Wen, Ph.D.
Promoting autophagic catabolism in chemoresistant ovarian cancer

2013

George A. Calin, MD, Ph.D.
Combinatorial therapy for ovarian cancer

Prahlad Ram, Ph.D.
MicroRNA biomarkers and therapy in ovarian cancer

2012

Alpa M. Nick, M.D.
Circulating tumor cells in ovarian cancer

Yuexin Liu, Ph.D.
Predicting therapy response in ovarian cancer

2011 

Wei Zhang, Ph.D.
MicroRNA therapy in ovarian cancer

Lois Ramondetta, M.D.
Targeting stress factors in ovarian cancer

2010

Kathleen Schmeler, MD
Inherited and sporadic BRCA alterations in ovarian cancer

Vahid Afshar-Kharghan, M.D.
The role of complement pathway in ovarian cancer

2009

Kwong K. Wong, Ph.D.
Understanding the molecular changes in cells that cause a rare ovarian cancer type: low grade serous carcinoma

2008

Bulent Ozpolat, M.D., Ph.D.
Tumor-targeting siRNA – nanovectors for novel molecular therapy of metastatic ovarian cancer

2007

Bryan Hennessy, M.D.
Proteomics to find markers of chemotherapy resistance in ovarian cancer

2006

Michael Frumovitz, M.D., M.P.H.
The study of quality of life in women receiving second-line chemotherapy for recurrent ovarian cancer

2005

Robert Luo, M.D., Ph.D. 
Evaluating tumor suppressor genes and apoptosis-independent autophagic cell death in ovarian cancer cells

2004

Lois Ramondetta, M.D.
Evaluating the role of spirituality in coping with and surviving ovarian cancer

Judith Ann Smith, Pharm.D., FCCP, BCOP
Evaluating the possible ways to reverse drug resistance during treatment of ovarian cancer

2003

Anil Sood, M.D.
How the neuroendocrine system regulates growth factors in ovarian cancer patients

Charlotte Sun, Dr.P.H., M.P.H.
Evaluating quality of life of patients receiving high dose chemotherapy for ovarian cancer

2002

Diane Bodurka, M.D. 
Evaluating the preferences of toxicities for ovarian cancer patients on chemotherapy

Rosemarie Schmandt, Ph.D.
The study of genetic alterations in a specific class of molecules known as kinases, that are frequently observed in the development of ovarian cancer tumors


© 2014 The University of Texas MD Anderson Cancer Center